HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Guidelines aim to ensure proper care of patients with sickle cell disease amid COVID-19 pandemic Jennifer Byrne
-
- How many errors to kill a population? Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Out of aces: Kenny Rogers, oncology and the novel coronavirus Rujuta Saksena, MD
- APP fellowships during COVID-19: One institution’s approach Camille Petraitis Valente, DNP, FNP-BC; Jessica M. Oser, DMSc, PA-C
- Convalescent plasma transfusion shows promise for severely ill patients with COVID-19 John DeRosier
- ‘Clarity with kindness’ key to easing COVID-19 anxiety among those with cancer Jennifer Byrne
- ‘Big strain’ on blood supply amid COVID-19 pandemic could force difficult decisions John DeRosier
- Myeloablative fractionated busulfan feasible as pre-HSCT regimen for older patients John DeRosier
- Toxicity minimal with novel transplantation approach for transfusion-dependent thalassemia John DeRosier
-
- Cytogenetic, molecular factors predict prognosis among patients who relapse after allogeneic HSCT Mark Leiser
- Lisocabtagene maraleucel active, safe, ‘worth considering’ in outpatient setting for lymphoma subset Drew Amorosi
- Primary letermovir prophylaxis prevents cytomegalovirus reactivation after haploidentical allogeneic HSCT Mark Leiser
- Tocilizumab may be effective for patients with COVID-19, blood cancer Mark Leiser
- Circulating tumor cells predictive of relapse in stage III melanoma John DeRosier
- H. pylori treatment reduces gastric cancer risk for certain individuals with family history of disease John DeRosier
- Talimogene laherparepvec-pembrolizumab combination appears safe, effective in advanced sarcoma John DeRosier
- Resection significantly extends survival in brainstem high-grade gliomas Jennifer R. Southall
-
- Combined biopsy approach improves prostate cancer detection John DeRosier
- Durvalumab plus chemotherapy, without tremelimumab, extends OS in small cell lung cancer
- SGX301 induces response in cutaneous T-cell lymphoma
- Melflufen induces response in triple-class refractory multiple myeloma
- Trial of dinutuximab for small cell lung cancer misses primary endpoint
- Phase 3 trial in relapsed ovarian cancer misses primary endpoint
- Phase 3 trial for transplant-ineligible myeloma misses endpoint
- Pembrolizumab-chemotherapy combination appears effective in metastatic triple-negative breast cancer
-
- Venetoclax regimen extends OS in treatment-naive acute myeloid leukemia
- Phase 3 trial for locally advanced head and neck cancer terminated
- Three agents receive breakthrough therapy designation
- FDA grants priority review to several therapies
- FDA panel supports approval of Cyramza regimen for EGFR-mutated metastatic NSCLC John DeRosier
- FDA grants fast track designation to IPI-549 for urothelial cancer
- FDA grants fast track designation to combination for advanced cervical cancer
- FDA approves Sevenfact for certain adults, adolescents with hemophilia
-
- FDA actions intended to improve safety of laparoscopic power morcellators for gynecologic surgery Drew Amorosi
- ASH, ASCO launch COVID-19 registries
- 12 medical centers form brain tumor research collaborative
- UCLA, UT Southwestern cancer centers join National Comprehensive Cancer Network
- Hematology scholars to participate in ASH faculty development program
- Foundation presents grants to six early career cancer researchers
- Association of Community Cancer Centers names new president
- GO2 Foundation presents Young Innovators Team Awards for lung cancer research
-
- AACR-MPM Oncology Charitable Foundation awards grants to cancer researchers
- Brain cancer specialist joins Mount Sinai faculty
- Radiation oncologist to lead clinical cancer research at Mount Sinai
- $1 million grants fund research into melanoma metastasis